[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Grégoire M, Ebstein F: [Immunotherapy and malignant mesothelioma: clinical perspectives]. Bull Cancer; 2007 Jan;94(1):23-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunotherapy and malignant mesothelioma: clinical perspectives].
  • Malignant pleural mesothelioma (MPM) is a rare malignancy of the pleura with a very poor prognosis.
  • Treatments evaluated for malignant mesothelioma, including chemotherapy, radiotherapy and surgery are of limited efficacy.
  • Clinical trials investigating new trends in the treatment of stage I and II malignant mesothelioma have shown both immunotherapy and systemic chemo-immunotherapy to be efficacious.
  • In addition, recent progresses in early detection techniques also provide hope that patients can be treated efficiently, at an earlier stage and well monitored.
  • Thus, immunotherapy of cancer is undoubtedly a highly promising but also very challenging approach in the treatment of a disease that has slipped through the defence lines of the immune system.
  • [MeSH-major] Immunotherapy / methods. Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Antigens, Neoplasm / immunology. Combined Modality Therapy / methods. Genetic Therapy / methods. Humans. Immunity, Cellular / immunology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237002.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Number-of-references] 70
  •  go-up   go-down


2. Jackevicius A, Cicenas S, Naujokaitis P, Piscikas D: [Diagnosis and treatment of pleural mesothelioma]. Medicina (Kaunas); 2002;38 Suppl 2:79-81
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of pleural mesothelioma].
  • The objective of our paper was to show the data of our treated patients with malignant pleural mesothelioma.
  • In the Department of Thoracic Surgery of Oncology Institute at Vilnius University from 1980 till 01.06.2002, 33 patients (pts), to whom diagnosis of pleural mesothelioma was confirmed by pathologist, were treated in the Clinic.
  • A malignant pleural mesothelioma was diagnosed in 31 pts, two pts had a non-malignant form of mesothelioma.
  • The distribution of pts according to the stage of the disease was: I stage - 3, II - 1, III - 17, IV - 10.
  • Videothoracoscopy is the best method for diagnosing pleural mesothelioma.
  • Adjuvant therapy (chemotherapy or radiotherapy) was given to 10 pts.
  • Diagnosis of malignant pleural mesothelioma is difficult and confirmation of the disease is possible only after histological examination of tumor.
  • 2. The best results of treatment were achieved after combined treatment: surgery, after chemotherapy and radiotherapy.
  • 3. In cases of pleural effusion of diffuse pleural mesothelioma insufflation of talc or other chemical substances into pleural cavity is recommended.
  • [MeSH-major] Mesothelioma. Pleural Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pleura / pathology. Pneumonectomy. Radiotherapy, Adjuvant. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12560629.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


3. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res; 2009 Jun 1;69(11):4598-604
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
  • Malignant pleural mesothelioma is an asbestos-related neoplasm with poor prognosis, refractory to current therapies, the incidence of which is expected to increase in the next decades.
  • Female gender was identified as a positive prognostic factor among other clinical and biological prognostic markers for malignant mesothelioma, yet a role of estrogen receptors (ERs) has not been studied.
  • Our goal was to investigate ERs expression in malignant mesothelioma and to assess whether their expression correlates with prognosis.
  • Immunohistochemical analysis revealed intense nuclear ERbeta staining in normal pleura that was reduced in tumor tissues.
  • Conversely, neither tumors nor normal pleura stained positive for ERalpha.
  • Multivariate analysis of 78 malignant mesothelioma patients with pathologic stage, histologic type, therapy, sex, and age at diagnosis indicated that ERbeta expression is an independent prognostic factor of better survival.
  • Moreover, studies in vitro confirmed that treatment with 17beta-estradiol led to an ERbeta-mediated inhibition of malignant mesothelioma cell proliferation as well as p21(CIP1) and p27(KIP1) up-regulation.
  • Our data support the notion that ERbeta acting as a tumor suppressor is of high potential relevance to prediction of disease progression and to therapeutic response of malignant mesothelioma patients.
  • [MeSH-major] Estrogen Receptor beta / metabolism. Estrogen Receptor beta / physiology. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis


Advertisement
4. Dienemann H, Trainer C: [Mesothelioma of the pleura and peritoneum. Diagnostic and therapeutic sequelae]. Chirurg; 2000 Aug;71(8):887-93
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mesothelioma of the pleura and peritoneum. Diagnostic and therapeutic sequelae].
  • [Transliterated title] Mesotheliom der Pleura und des Peritoneums. Diagnostische und therapeutische Folgerungen.
  • In patients with pleural or peritoneal mesothelioma, surgery is a technically difficult procedure.
  • Whereas those rare forms of localized pleural mesotheliomy are being detected incidentally and can be cured by complete resection, most patients with diffuse malignant mesothelioma present with an advanced stage of disease.
  • Most of these patients survive less than 12 months irrespective of the treatment modality.
  • For diffuse pleural mesothelioma, some favorable prognostic factors were identified: IMIG (International Mesothelioma Interest Group), stages I and II, epithelial type, age under 50, female gender.
  • For this subset of patients, a median survival time of between 20 and 30 months is reported.
  • Pleurectomy and decortication are recommended as palliative surgical strategies against pleural effusion.
  • In patients with technically inoperable infiltration of the thoracic wall, irradiation is helpful; sometimes partial remission and relief of pain can be achieved by chemotherapy.
  • [MeSH-major] Mesothelioma / surgery. Peritoneal Neoplasms / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11013807.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 21
  •  go-up   go-down


5. Cilla S, Digesú C, Silvano G, Macchia G, Massaccesi M, Deodato F, Padula GD, Fidanzio A, Piermattei A, Morganti AG: Intensity-modulated radiation therapy with simultaneous integrated boost in unresected left-sided pleural mesothelioma: a case report. Tumori; 2010 Jul-Aug;96(4):618-22
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy with simultaneous integrated boost in unresected left-sided pleural mesothelioma: a case report.
  • A 77-year-old male patient with unresected malignant pleural mesothelioma, clinical stage T3N0M0 according to the New International Staging System for Diffuse Malignant Pleural Mesothelioma, received intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) after 6 cycles of chemotherapy with cisplatin and pemetrexed.
  • SIB-IMRT delivered 40.5 Gy (1.5 Gy/fraction) to the left pleura and 50 Gy (1.85 Gy/fraction) to the sites of macroscopic disease.
  • Two months after the end of radiotherapy the patient showed grade 2 lung toxicity (febrile episodes accompanied by dry cough) that was successfully treated with steroid therapy.
  • Then the tumor recurred marginally to the radiation field and the patient underwent chemotherapy with pemetrexed.
  • To the best of our knowledge this is the first reported use of SIB-IMRT in unresected malignant pleural mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / radiotherapy. Pleural Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Dose Fractionation. Dyspnea / etiology. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Neoplasm Staging. Pemetrexed. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20968144.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Lucchi M, Chella A, Melfi F, Dini P, Tibaldi C, Fontanini G, Mussi A: Four-modality therapy in malignant pleural mesothelioma: a phase II study. J Thorac Oncol; 2007 Mar;2(3):237-42
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four-modality therapy in malignant pleural mesothelioma: a phase II study.
  • BACKGROUND: Treatment approaches in malignant pleural mesothelioma (MPM) patients range from mere palliation to aggressive anticancer therapy, and there is currently no consensus on the optimal therapeutic strategy.
  • In 1999, we began a phase II study to investigate four-modality treatment of advanced stage MPM.
  • METHODS: From 1999 to 2004, 49 patients with International Mesothelioma Interest Group stage II-III MPM underwent four-modality treatment with intrapleural preoperative interleukin-2 (18 x 10(6) UI/day for 3 days), pleurectomy/decortication, intrapleural postoperative epidoxorubicin (25 mg/m2 for 3 days), interleukin-2 (18 x 10(6) UI/day for 3 days), adjuvant radiotherapy (30 Gy), systemic chemotherapy (cisplatin 80 mg/m2 day 1, gemcitabine 1250 mg/m2 days 1 and 8 for up to six courses) and long-term subcutaneous interleukin-2 (3 x 10(6) UI/day on 3 days per week).
  • Baseline Eastern Cooperative Oncology Group performance status significantly influenced survival time (p = 0.02).
  • CONCLUSION: The four-modality treatment that we adopted for advanced-stage MPM was feasible, well tolerated by most of the patients, and produced a favorable median survival.
  • This treatment approach warrants further investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Epirubicin / administration & dosage. Epirubicin / analogs & derivatives. Feasibility Studies. Female. Humans. Interleukin-2 / administration & dosage. Male. Middle Aged. Pleura / surgery. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410047.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Chua TC, Yan TD, Morris DL: Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg; 2009 Feb;52(1):59-64
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.
  • Mesothelioma is an asbestos-related tumour.
  • Mesothelioma in the thorax occurs on the pleura and is known as pleural mesothelioma.
  • It is the more common form of mesothelioma, accounting for 70% of cases.
  • It accounts for much of the remaining 30% and is known as peritoneal mesothelioma.
  • Early diagnosis of peritoneal mesothelioma is often difficult because the early symptoms are often overlooked as being a benign ailment of the gastrointestinal tract.
  • Therefore, diagnosis often occurs at an advanced stage when disease is widespread throughout the peritoneal cavity.
  • Treatment approaches have evolved in the last decade from systemic chemotherapy and palliative surgery to aggressive cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • We update on the current understanding of peritoneal mesothelioma from a clinical perspective in hope that greater clinician awareness will promote best practice management of this condition.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Asbestos / adverse effects. Biomarkers, Tumor. Chemotherapy, Cancer, Regional Perfusion. Diagnostic Imaging. Endoscopy, Gastrointestinal. Humans. Hyperthermia, Induced

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):515-25 [17031722.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):41-9 [17039392.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1105-13 [17206478.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1807-17 [17342564.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2270-80 [17464543.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2047-52 [17434931.001]
  • [Cites] MedGenMed. 2007;9(2):32 [17955087.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1408-14 [17631678.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):125-33 [18030535.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] CMAJ. 2008 Mar 11;178(6):677-8 [18332380.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):247-50 [11500619.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):269-73 [12908781.001]
  • [Cites] Clin Lung Cancer. 2003 Nov;5(3):177-81 [14667274.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Lancet. 1985 Nov 2;2(8462):977-81 [2414612.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):369-73 [3035848.001]
  • [Cites] Environ Res. 1987 Oct;44(1):103-16 [3115771.001]
  • [Cites] Am J Pathol. 1987 Dec;129(3):448-62 [2827488.001]
  • [Cites] Exp Pathol. 1987;32(3):129-52 [3436395.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(7):547-50 [1624547.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):792-8 [7850791.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Environ Health Perspect. 1994 Dec;102 Suppl 10:131-6 [7705288.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Int J Occup Environ Health. 2005 Jul-Sep;11(3):254-8 [16130966.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):405-12 [16485159.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):41-5 [16767905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1615-9 [16600983.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:871-81 [17119263.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):500-8 [17151789.001]
  • (PMID = 19234654.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC2637623
  •  go-up   go-down


8. Lucchi M, Chella A, Melfi F, Dini P, Ambrogi M, Fino L, Fontanini G, Mussi A: A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2007 Mar;31(3):529-33; discussion 533-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
  • OBJECTIVE: From therapeutic nihilism to extremely aggressive management, there is a wide range of possibilities in the treatment of malignant pleural mesothelioma (MPM).
  • Unfortunately, there is little evidence as regards the best treatment to offer to the MPM patients.
  • In 1999, we started a phase II study based on the multimodality treatment of stage II-III MPM, the results of which have been analysed and reported.
  • METHODS: From 1999 to 2004, 49 patients with IMIG stage II-III MPM underwent a multimodality treatment including: intrapleural pre-operative interleukin 2 (IL-2, 18x10(6) UI/day per 3 days), pleurectomy/decortication, intrapleural post-operative epidoxorubicin (25mg/m2 per 3 days), IL-2 (18x10(6) UI/day per 3 days), adjuvant radiotherapy (30Gy), systemic chemotherapy (cisplatin 80 mg/m2 day 1, gemcitabine 1250 mg/m2 day 1 and 8 up to 6 courses) and long-term sub-cutaneous IL-2 (3x10(6) UI/day 3 days per week).
  • With a median follow-up of 59 months (range 14-81) 13 patients are still alive and the median actuarial survival is 26 months (31 and 21 months for stage II and III, respectively).
  • CONCLUSIONS: The multimodality treatment we adopted for stage II-III MPM was feasible, well tolerated by most of the patients and produced a favourable outcome.
  • New targeted therapies are awaited for further improvements in the treatment of this disease.
  • [MeSH-major] Mesothelioma / therapy. Pleura / surgery. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Drug Administration Schedule. Female. Humans. Interleukin-2 / therapeutic use. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Mar;31(3):534-5 [17267238.001]
  • (PMID = 17188885.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


9. Gupta NP, Kumar R: Malignant gonadal mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):363-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gonadal mesothelioma.
  • Malignant mesothelioma of the gonads is a rare and highly lethal disease.
  • Most of these tumors arise from the tunica vaginalis, which is a continuation of the mesothelium similar to the pleura and the peritoneum.
  • Occasionally, patients with localized disease at the time of detection have been known to survive for more than 10 years; however, the majority will not live beyond 5 years, with median survival being approximately 23 months.
  • The principle reasons for this are difficulty in making a preoperative diagnosis and advanced stage at the time of treatment.
  • Adjuvant therapy in the form of chemotherapy, immunotherapy, or radiotherapy has negligible benefit.
  • For advanced or recurrent disease, we suggest local radical resection with chemotherapy, including high-dose cisplatin and doxorubicin for two cycles of 5 days each; add local radiotherapy for uncontrolled locally advanced disease.
  • [MeSH-major] Genital Neoplasms, Male / drug therapy. Genital Neoplasms, Male / surgery. Mesothelioma / drug therapy. Mesothelioma / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Dec;144(6):1475-8 [2146405.001]
  • [Cites] Minerva Urol Nefrol. 2000 Mar;52(1):33-5 [11517828.001]
  • [Cites] Surg Today. 1999;29(10):1106-10 [10554340.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):294-306 [11202546.001]
  • [Cites] Br J Radiol. 1999 May;72(857):502-4 [10505018.001]
  • [Cites] Zentralbl Chir. 2001 Mar;126(3):229-32 [11301890.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Br J Urol. 1995 May;75(5):679-80 [7613813.001]
  • [Cites] Histopathology. 2000 Aug;37(2):150-9 [10931239.001]
  • [Cites] Jpn J Clin Oncol. 1991 Oct;21(5):377-83 [1753419.001]
  • [Cites] J Surg Oncol. 1999 Apr;70(4):251-4 [10219022.001]
  • [Cites] Ann Intern Med. 1984 Jan;100(1):19-24 [6197916.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):815-25 [7793480.001]
  • [Cites] Urol Int. 1995;55(4):215-7 [8588269.001]
  • (PMID = 12194801.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


10. Scagliotti GV, Selvaggi G: Emerging drugs for mesothelioma. Expert Opin Emerg Drugs; 2007 Mar;12(1):127-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for mesothelioma.
  • Malignant mesothelioma is an aggressive, but relatively rare, malignancy, affecting the pleura and peritoneum.
  • The prognosis for malignant pleural mesothelioma (MPM) is poor, with median survival in the range of 8-14 months, depending on stage and presentation of disease.
  • Long-term results of available treatments are disappointing not only in terms of prognosis, but also of local control of the disease.
  • Therefore, relief of symptoms and improvement of quality of life parameters are the short-term goals of therapy.
  • In advanced disease not amenable to any local approach, such as surgery, combination chemotherapy represents the current standard of care.
  • At present, the regimen of cisplatin/pemetrexed is the medical treatment of choice.
  • This review summarizes standard chemotherapy options and focuses on the molecular basis of the newest biologically targeted therapies to be implemented in the near future, in the management of MPM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355218.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


11. Giudicelli R: [Surgery for malignant pleural mesothelioma]. Rev Pneumol Clin; 2004 Apr;60(2):68-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery for malignant pleural mesothelioma].
  • [Transliterated title] Place actuelle de la chirurgie dans le traitement du mésothéliome pleural malin.
  • Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleura that is usually caused by exposure to asbestos.
  • Current surgical treatment involves in a multimodality regimen with radiation and multiple-drug chemotherapy.
  • All currently proposed therapeutic strategies are in total agreement with the international Mesothelioma Interest Group TNM staging system.
  • Schematically: for stage Ia (early stage disease), the therapeutic approach is generally neo-adjuvant intrapleural treatment using cytikines followed by surgical pleurectomy; for more advanced disease (stage Ib, II and III), a multimodal treatment combining extra-pleural pneumonectomy, radiotherapy and multiple-drug chemotherapy, including in all cases cisplatin, is proposed.
  • Recently, results using this multiple modality approach have been favorable especially for patients with epithelial histology, negative resection margins and no metastases to extrapleural lymph nodes; for stage IV (unresectable tumor), palliative treatment is indicated.
  • Early results have been encouraging and the use of recent drugs should allow more optimal treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Mesothelioma / surgery. Neoplasm Staging. Pleural Neoplasms / drug therapy. Pleural Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Incidence. Palliative Care. Prognosis. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15133442.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


12. Hirano H, Takeda S, Sawabata Y, Okumura Y, Maeda H, Hanibuchi M, Ito M, Nakagawa M, Uematsu K: Localized pleural malignant mesothelioma. Pathol Int; 2003 Sep;53(9):616-21
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized pleural malignant mesothelioma.
  • The occurrence of pleural malignant mesothelioma (MM) is unusual and the cases that appear as a localized tumor are extremely rare.
  • A case of localized pleural MM including immunohistochemical findings is presented.
  • Computed tomography (CT) showed an extrapleural mass with a smooth surface and a thickened parietal pleura, and results of a biopsy performed under CT scanning yielded MM.
  • Pathological examinations revealed that it consisted of large polygonal cells, partially showing myxoid patterns, which led to a diagnosis of localized pleural MM.
  • This case suggests that localized pleural MM has a high proliferative potential and aggressive course, and is considered an early stage of diffuse pleural MM.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Paclitaxel / therapeutic use. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14507319.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 24
  •  go-up   go-down


13. Tamura E, Kozaki M, Kunimoto M, Tokuyama S, Kawanami Y, Watanabe H, Hamada T, Morooka M, Mukae H: [A case of localized malignant pleural mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2010 Jul;48(7):511-5
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of localized malignant pleural mesothelioma].
  • A chest computed tomography (CT) scan revealed a 5-cm mass attached to the pleura involving the right upper lobe, and a nodule in the right middle lobe.
  • Transbronchial lung biopsy was performed twice, but no definitive diagnosis was achieved.
  • 18-fluorodeoxyglucose positron emission tomography showed abnormal uptake in the chest lesion.
  • Chemotherapy was initiated for advanced-stage lung cancer, but was not effective.
  • Histopathologic and immunohistochemical examinations after CT-guided needle biopsy revealed malignant mesothelioma.
  • There was local tumor invasion and metastasis in the lung and brain, without diffuse pleural spread.
  • This is a rare and important case of localized malignant mesothelioma pathologically confirmed by biopsy.
  • [MeSH-major] Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684215.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS, Pairolero PC: Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg; 2008 Jan;85(1):257-64; discussion 264
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: surgical management in 285 patients.
  • BACKGROUND: Malignant pleural mesothelioma is a rare, aggressive, and deadly malignancy.
  • Despite increasing incidence, no treatment modality is accepted standard of care.
  • This report analyzes our experience with surgical management of mesothelioma.
  • METHODS: All patients with surgery for mesothelioma from January 1985 through December 2003 were retrospectively reviewed.
  • Twenty patients were stage IA, 82 patients were stage IB, 24 patients were stage II, 75 patients were stage III, 60 patients were stage IV, and 24 patients were of unknown stage.
  • Fifty-three patients (19%) had chemotherapy alone, 16 (5.6%) had radiation alone, and 42 (14.7%) had both.
  • Thirty-day operative mortality was 6.3% and was not significantly associated with the operative procedure (p = 0.79).
  • Fifty-one percent of extrapleural pneumonectomy patients had major complications, significantly greater than patients having any other procedure (p < 0.001).
  • CONCLUSIONS: Extrapleural pneumonectomy can be performed with similar 30-day mortality as other procedures for malignant pleural mesothelioma with a median survival better than subtotal pleurectomy, exploration without resection, and biopsy alone.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / surgery. Pleural Neoplasms / pathology. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Needle. Confidence Intervals. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pleura / surgery. Probability. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18154820.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


15. Kent M, Rice D, Flores R: Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol; 2008 Jun;9(2-3):158-70
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.
  • OPINION STATEMENT: The clinical presentation of malignant pleural mesothelioma (MPM) is nonspecific.
  • Once the diagnosis is made, there is no universally accepted standard of care and treatment decisions are strongly influenced by physician bias.
  • Physicians who see few numbers of patients tend to treat based on symptoms alone by drainage of the pleural effusion and talc pleurodesis, while physicians at several tertiary referral centers tend to take an aggressive multimodality approach incorporating surgical resection, chemotherapy, and radiation.
  • The choice of operation, extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D), depends on disease stage, pulmonary function, philosophy of the treating physician, and type of planned adjuvant therapy.
  • [MeSH-major] Medical Oncology / methods. Mesothelioma / diagnosis. Mesothelioma / surgery. Neoplasm Staging / methods. Pleural Neoplasms / diagnosis. Pleural Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy / methods. Humans. Neoplasm Metastasis. Pleura / pathology. Pneumonectomy / methods. Positron-Emission Tomography / methods. Time Factors. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Apr 15;67(8):2033-7 [1672261.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3 [18329481.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):628-33 [9416409.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Oct;132(4):763-8 [17000285.001]
  • [Cites] Thorax. 1976 Feb;31(1):15-24 [1257933.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Jul;126(1):11-6 [12878934.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Feb;115(2):310-7; discussion 317-8 [9475525.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Sep;136(3):605-10 [18805259.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1156-63 [8201377.001]
  • [Cites] J Thorac Oncol. 2006 May;1(4):289-95 [17409872.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1157-68 [2666592.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1685-92; discussion 1692-3 [17954086.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):957-65 [17909360.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Chest. 1999 Aug;116(2):504-20 [10453882.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1561-7 [16575008.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 18758965.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


16. Watanabe S, Shimokawa S, Sakasegawa K, Nakamura Y, Sakata R: [Surgical treatment for malignant pleural mesothelioma in eight cases]. Kyobu Geka; 2000 Dec;53(13):1101-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for malignant pleural mesothelioma in eight cases].
  • Between 1987 and March 2000, we have operated on eight patients for malignant mesothelioma which consisted of four of localized type and four of diffuse type.
  • We have aggressively resected mesothelioma combined with chemotherapy whether the tumor was primary or recurrent, and concluded the following.
  • 1) In localized malignant mesothelioma, en-bloc primary tumor resection was possible and additional resection for recurrence was effective and useful for long time survival.
  • 2) In diffuse malignant mesothelioma, complete tumor resection was impossible to even perform pleuropneumonectomy accompanied with partial resection of pericardium and diaphragm and, therefore, the prognosis was poor in four patients and all died around one year.
  • 3) Because recurrent pattern for localized type was diffuse type, diagnosis and surgical treatment in early stage was essential for long time survival.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diaphragm / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Pericardium / surgery. Pleura / surgery. Pneumonectomy. Prognosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127555.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, Ménard O, Vuillez JP, Chokri M, Romet-Lemonne JL, Lopez M: Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest; 2002 Jun;121(6):1921-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study.
  • STUDY OBJECTIVES: Intrapleural immunotherapy has shown some activity in patients with malignant mesothelioma.
  • We conducted a multicentric pilot phase II study to evaluate the tolerance and the activity of intrapleurally infused autologous human activated macrophages (AM Phi) in patients with stage IA, IB, and IIA malignant pleural mesothelioma (MPM).
  • DESIGN: AM Phi derived from in vitro monocyte culture were infused into the pleura of patients every week for 8 consecutive weeks.
  • If the patient's disease progressed after AM Phi treatment, an additional treatment was left to the choice of the investigator.
  • PATIENTS: Nineteen patients with histologically proven stage IA, IB, or IIA MPM were enrolled.
  • After completion of the AM Phi cellular therapy, 10 patients were treated with chemotherapy as their diseases progressed.
  • One patient, who could not be evaluated by thoracoscopy because of pleural symphysis, is still alive without any clinical or radiologic sign of disease 69 months after treatment.
  • No major adverse effects were observed during the infusion of either AM Phi or gamma-IFN, and there was no interruption of treatment because of toxicity.
  • However, symphysis was observed in 7 of 14 patients who received the complete treatment.
  • The median survival of patients actually treated, including those who received chemotherapy after AM Phi, was 29.2 months.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-gamma / administration & dosage. Macrophages / physiology. Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Female. Humans. Immunotherapy / methods. Infusions, Parenteral. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Pleura

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065358.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


18. Trousse DS, Avaro JP, D'Journo XB, Doddoli C, Astoul P, Giudicelli R, Fuentes PA, Thomas PA: Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg; 2009 Oct;36(4):759-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
  • OBJECTIVE: To report on the experience with radical surgery, with emphasis on the long-term outcome, for malignant pleural mesothelioma (MPM) at a single institution.
  • RESULTS: A total of 83 patients (65 males, median age: 60 years) underwent an extra-pleural pneumonectomy (EPP) with a curative intent.
  • The International Mesothelioma Interest Group (IMIG) stage of the disease was 2 in 36%, 3 in 45% and 4 in 9% of the cases.
  • Preoperative chemotherapy consisting of a doublet cisplatin-pemetrexed (mean of three cycles) was offered to 10 patients (12%).
  • Postoperative therapies, either chemotherapy or radiotherapy, were given in 25 patients (30%).
  • Re-operation was necessary in 12 cases (14.5%) for one of the following reasons: broncho-pleural fistula (n=4), bleeding (n=3), diaphragmatic patch rupture (n=3), oesophago-pleural fistula (n=1) and empyaema (n=1).
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pleura / surgery. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19523843.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


19. Tomera JF: Mesothelioma: Drug treatment and other interventions. Drugs Today (Barc); 2000 Oct;36(10):689-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma: Drug treatment and other interventions.
  • Malignant mesothelioma was reported to be a tumor of the pleura for which there is no satisfactory treatment.
  • It was also reported to be almost universally fatal, regardless of the stage of the tumor at the time of diagnosis.
  • Due to the dismal prognosis for patients with this malignant disease, a new mode of treatment is desperately needed.
  • Current drugs and other interventional modalities which include surgery, chemotherapy and radiation therapy are discussed below.
  • However, in some patients none of these modalities are superior to absence of treatment.
  • Discussed within this article are single agent and combined chemomodality therapy studies, target ligands, radiation-sensitizing and antiviral agents, multimodality and gene therapy, and chemoresistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12847573.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


20. Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M: Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer; 2001 Feb-Mar;31(2-3):303-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
  • Malignant pleural mesothelioma is often unresectable at diagnosis, is refractory to cytotoxic agents and is frequently complicated by pleural effusion.
  • The expected survival range for patients with or without involvement of visceral pleura is respectively 1-9 and 9-12 months; mesothelioma-related pleural effusion severely impairs the patients' quality of life and easily relapses after conservative treatments.
  • Intrapleural administration of IL-2 is reported to be effective both in tumor-associated malignant pleurisy and on primary mesothelioma, whereas few data exist about IL-2 systemic administration.
  • In order to assess the palliative and therapeutic activity of IL-2 in unresectable pleural malignant mesothelioma with pleural effusion, we performed a phase II study on 31 consecutive patients (M/F 16/15; median age 61 years, range 40-84; PS ECOG 0 n=7; ECOG 1 n=15; ECOG 2 n=9; stage IA n=13; IB n=9; II n=7; IV=2) who received first-line therapy with intrapleural repeated instillation of 9000000 I.U.
  • Toxicity (WHO criteria) with intrapleural IL-2 consisted of grade 3 fever in 6/31 (19%) patients and of cardiac toxicity (failure) grade 3 in one patient (3%); toxicity during subcutaneous treatment was mild to moderate, mainly a flu-like syndrome.
  • In 28/31 (90%) of patients there was no further or minimal (asymptomatic) pleural fluid collection (according to Paladine criteria); pleurisy relapsed only in 1/28 patients after 19 months.
  • IL-2 intrapleural administration followed by low-dose IL-2 subcutaneously in pleurisy-complicated malignant mesothelioma is feasible and active both in palliation of pleural effusion and on primary tumor, with manageable toxicity.
  • [MeSH-major] Interleukin-2 / therapeutic use. Mesothelioma / drug therapy. Pleural Effusion / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11165411.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


21. Rusch VW: A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2007 Mar;31(3):534-5
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Humans. Interleukin-2 / therapeutic use. Pleura / surgery. Radiotherapy, Adjuvant. Research Design

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur J Cardiothorac Surg. 2007 Mar;31(3):529-33; discussion 533-4 [17188885.001]
  • (PMID = 17267238.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down






Advertisement